ANDA 202692, held by Altaire Pharms Inc. Ofloxacin.
As of Nov 16, 2026, ANDA 202692 (Ofloxacin), held by Altaire Pharms Inc, was first approved by FDA on Apr 29, 2013, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Ofloxacin ophthalmic solution, USP is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumonia Enterobacter cloacae Haemophilus influenza Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Pseudomonas aeruginosa Serratia marcascens ' Anaerobic species: Propionibacterium acnes * Efficacy for this organism was studied in fewer than 10 infec…
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 29, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ofloxacin0.3% · solution/drops;ophthalmic | Ofloxacin | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters